GlassScriptPhysician profile
Ralph Michael Wisniewski
NPI 1992770309
$5,799.58
in general payments reported to CMS, 2019-2025
28 companies · $740 in 2025
The $740 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $923 · 2020: $389 · 2021: $952 · 2022: $935 · 2023: $868 · 2024: $993 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,599.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,828.10 | 2019-2025 | Skyrizi, Linzess, Rinvoq |
| Janssen Biotech, INC. | $1,185.71 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $498.26 | 2019-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $248.51 | 2019-2024 | Entyvio, Gattex |
| Qol Medical, LLC | $238.97 | 2021-2024 | Sucraid, Sucraid |
| Regeneron Healthcare Solutions, INC. | $209.06 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.43 | 2019-2023 | Xifaxan, Trulance |
| Covidien LP | $170.64 | 2019 | |
| Daiichi Sankyo INC. | $131.51 | 2021-2022 | |
| Davol INC. | $130.30 | 2019 | |
| Pfizer INC. | $125.79 | 2019-2025 | |
| Ucb, INC. | $113.76 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $105.81 | 2021 | |
| Celgene Corporation | $99.22 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $76.03 | 2024-2025 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $69.24 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $56.60 | 2019-2024 | Dificid |
| Ardelyx, INC. | $52.12 | 2023-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $40.88 | 2024-2025 | Zenpep |
| Medtronic, INC. | $39.61 | 2024-2025 | Gi Genius, Pillcam |
| Capsovision, INC. | $39.39 | 2024 | Capsocam Plus |
| Genzyme Corporation | $37.23 | 2019-2023 | |
| Lilly USA, LLC | $36.71 | 2025 | Omvoh |
| Amgen INC. | $19.60 | 2020 | |
| Madrigal Pharmaceuticals | $17.79 | 2024 | Resmetirom |
| Ipsen Biopharmaceuticals, INC | $16.53 | 2024 | Bylvay |
| Intercept Pharmaceuticals, INC. | $14.61 | 2024 | |
| Braintree Laboratories, INC. | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Wisniewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.